Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-514, its Lead Core Inhibitor for the Treatment of Hepatitis B Virus (HBV)


WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has initiated part 1 of a Phase 1a/b clinical study of EDP-514, Enanta’s lead core inhibitor for the treatment of hepatitis B virus (HBV). The randomized, double-blind, placebo-controlled Phase 1a/b study is designed to evaluate first the safety,…